<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type='text/xsl' href='../../ld1webpage.xsl'?>
<LOBBYINGDISCLOSURE1>
  <imported>N</imported>
  <pages>2</pages>
  <regType>2</regType>
  <organizationName>Akin Gump Strauss Hauer &amp; Feld</organizationName>
  <prefix>
  </prefix>
  <firstName>
  </firstName>
  <lastName>
  </lastName>
  <address1>1333 NEW HAMPSHIRE AVE., NW</address1>
  <address2>
  </address2>
  <city>WASHINGTON</city>
  <state>DC</state>
  <zip>20036</zip>
  <zipext>
  </zipext>
  <country>USA</country>
  <principal_city>
  </principal_city>
  <principal_state>
  </principal_state>
  <principal_zip>
  </principal_zip>
  <principal_zipext>
  </principal_zipext>
  <principal_country>
  </principal_country>
  <contactIntlPhone>
  </contactIntlPhone>
  <registrantGeneralDescription>Law firm</registrantGeneralDescription>
  <selfSelect>N</selfSelect>
  <clientName>Akebia Therapeutics, Inc.</clientName>
  <clientAddress>245 First Street, Suite 1400</clientAddress>
  <clientCity>Cambridge</clientCity>
  <clientState>MA</clientState>
  <clientZip>02142</clientZip>
  <clientZipExt>
  </clientZipExt>
  <clientCountry>USA</clientCountry>
  <prinClientCity>
  </prinClientCity>
  <prinClientState>
  </prinClientState>
  <prinClientZip>
  </prinClientZip>
  <prinClientZipExt>
  </prinClientZipExt>
  <prinClientCountry>
  </prinClientCountry>
  <clientGeneralDescription>Therapeutic solutions leveraging the potential of hypoxia inducible factor (HIF) biology</clientGeneralDescription>
  <senateID>682</senateID>
  <houseID>317840818</houseID>
  <lobbyists>
    <lobbyist>
      <lobbyistFirstName>John</lobbyistFirstName>
      <lobbyistLastName>Jonas</lobbyistLastName>
      <lobbyistSuffix>
      </lobbyistSuffix>
      <coveredPosition>
      </coveredPosition>
      <lobbyistNew>Y</lobbyistNew>
    </lobbyist>
    <lobbyist>
      <lobbyistFirstName>Heide</lobbyistFirstName>
      <lobbyistLastName>Bajnrauh</lobbyistLastName>
      <lobbyistSuffix>
      </lobbyistSuffix>
      <coveredPosition>Sen McCain LSA, 96-97</coveredPosition>
      <lobbyistNew>Y</lobbyistNew>
    </lobbyist>
    <lobbyist>
      <lobbyistFirstName>Todd</lobbyistFirstName>
      <lobbyistLastName>Tuten</lobbyistLastName>
      <lobbyistSuffix>
      </lobbyistSuffix>
      <coveredPosition>Rep Michael Bilirakis; 91-92, 93-95, 98-01</coveredPosition>
      <lobbyistNew>Y</lobbyistNew>
    </lobbyist>
    <lobbyist>
      <lobbyistFirstName>Julie</lobbyistFirstName>
      <lobbyistLastName>Nolan</lobbyistLastName>
      <lobbyistSuffix>
      </lobbyistSuffix>
      <coveredPosition>Deputy CoS and LD, Nov.17-Nov. 18; LD, Nov.16-17; LA Oct. 15-16 to
Rep. Patrick Meehan; Staff Asst, Sen. Richard Lugar Jan. 06-Jan. 07.</coveredPosition>
      <lobbyistNew>Y</lobbyistNew>
    </lobbyist>
    <lobbyist>
      <lobbyistFirstName>
      </lobbyistFirstName>
      <lobbyistLastName>
      </lobbyistLastName>
      <lobbyistSuffix>
      </lobbyistSuffix>
      <coveredPosition>
      </coveredPosition>
      <lobbyistNew>N</lobbyistNew>
    </lobbyist>
  </lobbyists>
  <alis>
    <ali_Code>HCR</ali_Code>
    <ali_Code>MMM</ali_Code>
    <ali_Code>
    </ali_Code>
    <ali_Code>
    </ali_Code>
    <ali_Code>
    </ali_Code>
    <ali_Code>
    </ali_Code>
    <ali_Code>
    </ali_Code>
    <ali_Code>
    </ali_Code>
    <ali_Code>
    </ali_Code>
  </alis>
  <specific_issues>Reverse CMS decision to remove Auryxia from the Part D formulary.</specific_issues>
  <affiliatedUrl>
  </affiliatedUrl>
  <affiliatedOrgs>
    <affiliatedOrg>
      <affiliatedOrgName>
      </affiliatedOrgName>
      <affiliatedOrgAddress>
      </affiliatedOrgAddress>
      <affiliatedOrgCity>
      </affiliatedOrgCity>
      <affiliatedOrgState>
      </affiliatedOrgState>
      <affiliatedOrgZip>
      </affiliatedOrgZip>
      <affiliatedOrgCountry>
      </affiliatedOrgCountry>
      <affiliatedPrinOrgCity>
      </affiliatedPrinOrgCity>
      <affiliatedPrinOrgState>
      </affiliatedPrinOrgState>
      <affiliatedPrinOrgCountry>
      </affiliatedPrinOrgCountry>
    </affiliatedOrg>
    <affiliatedOrg>
      <affiliatedOrgName>
      </affiliatedOrgName>
      <affiliatedOrgAddress>
      </affiliatedOrgAddress>
      <affiliatedOrgCity>
      </affiliatedOrgCity>
      <affiliatedOrgState>
      </affiliatedOrgState>
      <affiliatedOrgZip>
      </affiliatedOrgZip>
      <affiliatedOrgCountry>
      </affiliatedOrgCountry>
      <affiliatedPrinOrgCity>
      </affiliatedPrinOrgCity>
      <affiliatedPrinOrgState>
      </affiliatedPrinOrgState>
      <affiliatedPrinOrgCountry>
      </affiliatedPrinOrgCountry>
    </affiliatedOrg>
    <affiliatedOrg>
      <affiliatedOrgName>
      </affiliatedOrgName>
      <affiliatedOrgAddress>
      </affiliatedOrgAddress>
      <affiliatedOrgCity>
      </affiliatedOrgCity>
      <affiliatedOrgState>
      </affiliatedOrgState>
      <affiliatedOrgZip>
      </affiliatedOrgZip>
      <affiliatedOrgCountry>
      </affiliatedOrgCountry>
      <affiliatedPrinOrgCity>
      </affiliatedPrinOrgCity>
      <affiliatedPrinOrgState>
      </affiliatedPrinOrgState>
      <affiliatedPrinOrgCountry>
      </affiliatedPrinOrgCountry>
    </affiliatedOrg>
  </affiliatedOrgs>
  <foreignEntities>
    <foreignEntity>
      <name>
      </name>
      <address>
      </address>
      <city>
      </city>
      <state>
      </state>
      <country>
      </country>
      <prinCity>
      </prinCity>
      <prinState>
      </prinState>
      <prinCountry>
      </prinCountry>
      <contribution>
      </contribution>
      <ownership_Percentage>
      </ownership_Percentage>
    </foreignEntity>
    <foreignEntity>
      <name>
      </name>
      <address>
      </address>
      <city>
      </city>
      <state>
      </state>
      <country>
      </country>
      <prinCity>
      </prinCity>
      <prinState>
      </prinState>
      <prinCountry>
      </prinCountry>
      <contribution>
      </contribution>
      <ownership_Percentage>
      </ownership_Percentage>
    </foreignEntity>
  </foreignEntities>
  <reportYear>2019</reportYear>
  <reportType>RR</reportType>
  <effectiveDate>2/1/19</effectiveDate>
  <printedName>Brian Pomper</printedName>
  <signedDate>3/13/2019 7:00:48 PM</signedDate>
</LOBBYINGDISCLOSURE1>